XML 16 R1.htm IDEA: XBRL DOCUMENT v3.25.3
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 27, 2025
Jun. 30, 2024
Document Type 10-K/A    
Amendment Flag true    
Amendment Description This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2024, as originally filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2025 (the “Original 10-K”). The purpose of this Amendment is to incorporate the report of the current independent registered public accounting firm following their re-audit of both the full year 2024 and 2023 financial periods. The re-audit of these periods was conducted at the request of management to bring about efficiencies and future cost savings by placing reliance on a single audit firm to provide auditor consents for future registration statements and similar filings. In addition, except as otherwise indicated, all information in this Amendment assumes a 1-for-16 stock split effective May 7, 2025 of the outstanding common stock of the Company and a 1-for-15 stock split effective July 2, 2025 of the outstanding common stock of the Company.   Furthermore, on September 12, 2025, the Company changed its name to Bio Green Med Solution Inc. and this Amendment is being filed under this new name. However, all Company name references within this document remain as Cyclacel Pharmaceuticals, Inc.   Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the dates described in the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original 10-K, as information in such filings may update or supersede certain information contained in this Amendment. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Part III, Item 12 of the Original 10-K is hereby amended and restated in its entirety and new certifications by our principal executive officer and principal financial officer required by Rule 13a-14(a) under the Exchange Act are also being filed as exhibits to this Amendment. This Amendment speaks as of the filing date of the Original 10-K, does not reflect events that may have occurred subsequent such date, and does not amend or otherwise update any other information in the Original 10-K. Accordingly, this Amendment should be read in conjunction with the Original 10-K and with our filings with the SEC subsequent to the Original 10-K.   In this Amendment, unless the context specifically indicates otherwise, “the Company,” “we,” “us,” “our,” and “Cyclacel” refer to Cyclacel Pharmaceuticals, Inc. and its subsidiaries.      
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 00-50626    
Entity Registrant Name Bio Green Med Solution, Inc.    
Entity Central Index Key 0001130166    
Entity Tax Identification Number 91-1707622    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One Level 10, Tower 11    
Entity Address, Address Line Two Avenue 5, No. 8    
Entity Address, Address Line Three Jalan Kerinchi    
Entity Address, City or Town Kuala Lumpur    
Entity Address, Country MY    
Entity Address, Postal Zip Code 59200    
City Area Code (908)    
Local Phone Number 955-0526    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 2,523,882
Entity Common Stock, Shares Outstanding   863,901  
Documents Incorporated by Reference [Text Block] The following document (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant’s definitive proxy statement for the 2025 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2024. Except with respect to information specifically incorporated by reference in this Form 10-K, the Definitive Proxy Statement is not deemed to be filed as part of this Form 10-K.    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheet of Bio Green Med Solution, Inc. (Formerly known as Cyclacel Pharmaceuticals, Inc.) and its subsidiary (collectively, the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations (loss) and other comprehensive loss, stockholders’ equity and cash flows for each of the years ended December 31, 2024 and 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years ended December 31, 2024 and 2023, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name SFAI Malaysia PLT    
Auditor Location Malaysia    
Auditor Firm ID 7167    
Common Stock, par value $0.001 per share [Member]      
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol CYCC    
Security Exchange Name NASDAQ    
Preferred Stock, $0.001 par value [Member]      
Title of 12(b) Security Preferred Stock, $0.001 par value    
Trading Symbol CYCCP    
Security Exchange Name NASDAQ